Amgen
-
Amgen Inc.(AMGN) Q3: EPS 6.45 USD (above forecast), Revenue 10.37B USD (above forecast)
Amgen Inc.(AMGN) Q3 EPS: 6.45 USD; Forecast 5.79 USD Revenue: 10.37B USD; Forecast 10.07B USD Reporting period: 2026 Q3 (period ended 2026-09-30) Release date: 2026-11-03
-
Yahoo Finance analysis: Vertex Pharmaceuticals is a better healthcare stock buy than Amgen in 2026
The analysis highlights that Vertex Pharmaceuticals, with its dominant cystic fibrosis franchise and expansion into new disease areas like sickle cell disease, is growing faster and boasts superior op
-
Yahoo Finance Analysis: Amgen is a More Robust Healthcare Stock Investment Choice Than CRISPR Therapeutics in 2026
Yahoo Finance analysis suggests that in 2026, traditional pharmaceutical giant Amgen is a more stable investment choice compared to gene-editing pioneer CRISPR Therapeutics. The report indicates that
-
Yahoo Finance analyst recommends Amgen over Moderna for 2026, citing Amgen's stability and profitability against Moderna's pipeline risks
The analyst highlights Amgen's veteran status in drug manufacturing, focusing on diverse treatments for chronic conditions, with revenue reaching nearly $36.7 billion in FY 2025 and a net income of ap
-
Novartis's cholesterol drug Pelacarsen fails to significantly improve cardiovascular outcomes in Phase III trial; Amgen and Ionis shares decline.
Novartis announced after market close on Friday that its cholesterol drug Pelacarsen, co-developed with Ionis Pharmaceuticals, failed to significantly improve cardiovascular outcomes in late-stage cli
-
Amgen Hikes Sales Outlook By $1 Billion After Second-Quarter Smash
Amgen Hikes Sales Outlook By $1 Billion After Second-Quarter Smash
-
Amgen Inc.(AMGN) Q3: EPS 6.45 USD (above forecast), Revenue 10.37B USD (above forecast)
Amgen Inc.(AMGN) Q3 EPS: 6.45 USD; Forecast 5.79 USD Revenue: 10.37B USD; Forecast 10.07B USD Reporting period: 2026 Q3 (period ended 2026-09-30) Release date: 2026-11-03
-
Yahoo Finance analysis: Vertex Pharmaceuticals is a better healthcare stock buy than Amgen in 2026
The analysis highlights that Vertex Pharmaceuticals, with its dominant cystic fibrosis franchise and expansion into new disease areas like sickle cell disease, is growing faster and boasts superior op
-
Yahoo Finance Analysis: Amgen is a More Robust Healthcare Stock Investment Choice Than CRISPR Therapeutics in 2026
Yahoo Finance analysis suggests that in 2026, traditional pharmaceutical giant Amgen is a more stable investment choice compared to gene-editing pioneer CRISPR Therapeutics. The report indicates that
-
Yahoo Finance analyst recommends Amgen over Moderna for 2026, citing Amgen's stability and profitability against Moderna's pipeline risks
The analyst highlights Amgen's veteran status in drug manufacturing, focusing on diverse treatments for chronic conditions, with revenue reaching nearly $36.7 billion in FY 2025 and a net income of ap
-
Novartis's cholesterol drug Pelacarsen fails to significantly improve cardiovascular outcomes in Phase III trial; Amgen and Ionis shares decline.
Novartis announced after market close on Friday that its cholesterol drug Pelacarsen, co-developed with Ionis Pharmaceuticals, failed to significantly improve cardiovascular outcomes in late-stage cli
-
Amgen Hikes Sales Outlook By $1 Billion After Second-Quarter Smash
Amgen Hikes Sales Outlook By $1 Billion After Second-Quarter Smash
- No data
Amgen
24H Trending
-
1
Lombard (BARD) Token Analysis: Value, Investment Potential, and Risk Assessment
-
2
A Review of Major Global Digital Currency Trading Platforms and Market Landscape
-
3
Antminer S9 Retirement: Bitcoin Hashrate Doesn't Plummet, Continues to Grow
-
4
Bitcoin Leveraged Trading Analysis: Definition, Operations, and Risk Management
-
5
CARR Token: An Analysis of the Carnomaly Project and Its Blockchain Applications in the Automotive Industry
-
6
A Rundown of Major Global Crypto Exchanges and Fee Comparison: How to Choose a Low-Cost Platform?
-
7
WSI Token: Role and Future Outlook of the WeSendit Decentralized File Sharing Platform
-
8
TATA Coin: Value and Long-Term Investment Considerations for a Community-Driven Token
-
9
OKX Futures vs. HTX Futures: A Comparative Analysis of Market Position, Fees, and Features
-
10
The Digital Currency Era: Fintech's Opportunities and Challenges Coexist
Markets Today
Recommended Reading





